Figure 1.
Probability according to DNMT3A mutations. The probability of overall survival (A), cumulative incidence of relapse (B), and disease-free survival (C) in patients with AML according to DNMT3A mutations. Overall survival (D), cumulative incidence of relapse (E), and disease-free survival (F) in triple-mutated (TM-AML) patients. Survival curves were estimated using the Kaplan-Meier method, and the log‐rank test was used for comparison. Cumulative incidence curves for nonrelapse death and relapse with or without death were constructed to reflect time to relapse and time to nonrelapse death as competing risks. Time to relapse and time to nonrelapse death were measured from the date of complete remission. Multivariate Cox model for overall survival (G) and disease-free survival (H).

Probability according to DNMT3A mutations. The probability of overall survival (A), cumulative incidence of relapse (B), and disease-free survival (C) in patients with AML according to DNMT3A mutations. Overall survival (D), cumulative incidence of relapse (E), and disease-free survival (F) in triple-mutated (TM-AML) patients. Survival curves were estimated using the Kaplan-Meier method, and the log‐rank test was used for comparison. Cumulative incidence curves for nonrelapse death and relapse with or without death were constructed to reflect time to relapse and time to nonrelapse death as competing risks. Time to relapse and time to nonrelapse death were measured from the date of complete remission. Multivariate Cox model for overall survival (G) and disease-free survival (H).

Close Modal

or Create an Account

Close Modal
Close Modal